Education
About Us
Working with TipRanks
Follow Us
Diagonal Bio AB (DE:9F1)
FRANKFURT:9F1
Total Valuation
Diagonal Bio AB has a market cap or net worth of €1.22M. The enterprise value is ―.
Market Cap€1.22M
Enterprise Value―
Share Statistics
Diagonal Bio AB has 1,214,965,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,214,965,300
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Diagonal Bio AB’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee3.83K
Profits Per Employee-1.95M
Employee Count6
Asset Turnover<0.01
Inventory Turnover-3.03
Valuation Ratios
The current PE Ratio of Diagonal Bio AB is -1.03. Diagonal Bio AB’s PEG ratio is -0.01.
PE Ratio-1.03
PS Ratio0.00
PB Ratio0.20
Price to Fair Value0.56
Price to FCF-0.94
Price to Operating Cash Flow-0.41
PEG Ratio-0.01
Income Statement
In the last 12 months, Diagonal Bio AB had revenue of 23.00K and earned -11.68M in profits. Earnings per share was -0.32.
Revenue23.00K
Gross Profit3.13M
Operating Income-11.57M
Pretax Income-11.68M
Net Income-11.68M
EBITDA-11.47M
Earnings Per Share (EPS)-0.32
Cash Flow
In the last 12 months, operating cash flow was -12.90M and capital expenditures -4.62M, giving a free cash flow of -17.53M billion.
Operating Cash Flow-12.90M
Free Cash Flow-17.53M
Free Cash Flow per Share-0.01
Dividends & Yields
Diagonal Bio AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta7.24
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)0.00
Important Dates
Diagonal Bio AB upcoming earnings date is Aug 22, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateAug 22, 2025
Ex-Dividend Date―
Financial Position
Diagonal Bio AB as a current ratio of 0.65, with Debt / Equity ratio of 0.00%
Current Ratio0.65
Quick Ratio0.51
Debt to Market Cap0.00
Net Debt to EBITDA―
Interest Coverage Ratio-56.15
Taxes
In the past 12 months, Diagonal Bio AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Diagonal Bio AB EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Diagonal Bio AB has €1.73M in cash and marketable securities with kr0.00 in debt, giving a net cash position of -€1.73M billion.
Cash & Marketable Securities€1.73M
Total Debtkr0.00
Net Cash-€1.73M
Net Cash Per Share>-€0.01
Tangible Book Value Per Share-€0.07
Margins
Gross margin is -419.75%, with operating margin of -50286.96%, and net profit margin of -50773.91%.
Gross Margin-419.75%
Operating Margin-50286.96%
Pretax Margin-50773.91%
Net Profit Margin-50773.91%
EBITDA Margin-49865.22%
EBIT Margin-49878.26%
Analyst Forecast
The average price target for Diagonal Bio AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―